Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271547 | 0.93 | MMP1 (0.49) | SMN1; SMN2HIF1AMMP1MMP9MMP13 | |
| SCHEMBL19182977 | 0.92 | PPARG (0.46) | SMN1; SMN2HIF1AMMP1MMP9MMP13 | |
| SCHEMBL3159710 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1AMMP1MMP9MMP13 | |
| SCHEMBL28755706 | 0.88 | PPARA (0.49) | SMN1; SMN2HIF1AMMP1MMP9MMP13 | |
| SCHEMBL28106001 | 0.87 | BLM (0.54) | HIF1APPARGPPARAPPARDSLC6A2 | |
| SCHEMBL20715652 | 0.87 | PPARG (0.48) | MMP1MMP9MMP13PPARGPPARA | |
| SCHEMBL19182947 | 0.87 | PPARG (0.48) | MMP1MMP9MMP13PPARGPPARA | |
| SCHEMBL28206355 | 0.85 | MMP8 (0.48) | MMP1MMP9MMP13CTSKMMP8 | |
| SCHEMBL25046029 | 0.84 | ALDH1A1 (0.53) | EPHX2ALDH1A1CYP3A4CYP2C19KMT2A | |
| SCHEMBL6875021 | 0.83 | MAPT (0.50) | SMN1; SMN2HIF1APPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819637-B1 | FIXING OF PERFUME ON WET SKIN | BEIERSDORF AG (DE) | 2017-08-23 | — | — | EP | claimed |
| EP-0204736-B1 | PROCESS FOR THE PREPARATION OF BENZENE DERIVATIVES | L. GIVAUDAN & CIE Société Anonyme (CH) | 1989-07-26 | — | — | EP | claimed |
| EP-0204736-A1 | PROCESS FOR THE PREPARATION OF BENZENE DERIVATIVES. | GIVAUDAN & CIE SA (CH) | 1986-12-17 | — | — | EP | claimed |
| WO-1986003486-A1 | PROCESS FOR THE PREPARATION OF BENZENE DERIVATIVES | L. GIVAUDAN & CIE SOCIÉTÉ ANONYME (CH) | 1986-06-19 | — | — | WO | claimed |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-1920042-B1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL AG & CO KGAA (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-1920042-A1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007118747-A1 | AQUEOUS CLEANING AGENT CONTAINING PERFUME | HENKEL AG & CO. KGAA (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007028480-A1 | PARTICLES CONTAINING ZEOLITE AND PERFUME HAVING IMPROVED FRAGRANCE PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028478-A1 | PARTICLES CONTAINING PERFUME HAVING IMPROVED FRAGRANCED PROPERTIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | disclosed |
| EP-0204736-B1 | PROCESS FOR THE PREPARATION OF BENZENE DERIVATIVES | L. GIVAUDAN & CIE Société Anonyme (CH) | 1989-07-26 | — | — | EP | disclosed |
| EP-0204736-A1 | PROCESS FOR THE PREPARATION OF BENZENE DERIVATIVES. | GIVAUDAN & CIE SA (CH) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003486-A1 | PROCESS FOR THE PREPARATION OF BENZENE DERIVATIVES | L. GIVAUDAN & CIE SOCIÉTÉ ANONYME (CH) | 1986-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | SMN1; SMN2 4174/4885HIF1A 1517/4885MMP1 4883/4885 |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | SMN1; SMN2 4174/4885HIF1A 1517/4885MMP1 4883/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | SMN1; SMN2 4174/4885HIF1A 1517/4885MMP1 4883/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | SMN1; SMN2 4174/4885HIF1A 1517/4885MMP1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.